Cargando…

The Oncolytic Activity of Myxoma Virus against Soft Tissue Sarcoma Is Mediated by the Overexpression of Ribonucleotide Reductase

BACKGROUND: Myxoma virus (MYXV) is an oncolytic poxvirus that lacks the gene for 1 of the subunits of ribonucleotide reductase (RR), a crucial DNA synthesis and repair enzyme. The overexpression of RR has been implicated in the invasiveness of several cancers, including soft tissue sarcomas (STS). T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Woo, Yanghee, Warner, Susanne G, Geha, Rula, Stanford, Marianne M, Decarolis, Penelope, Rahman, Masmudur M, Singer, Samuel, McFadden, Grant, Fong, Yuman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887694/ https://www.ncbi.nlm.nih.gov/pubmed/33633477 http://dx.doi.org/10.1177/1179554921993069

Ejemplares similares

Oncolytic Virotherapy with Myxoma Virus
por: Rahman, Masmudur M., et al.
Publicado: (2020)

Identification of host DEAD-box RNA helicases that regulate cellular tropism of oncolytic Myxoma virus in human cancer cells
por: Rahman, Masmudur M., et al.
Publicado: (2017)

NSCs are permissive to oncolytic Myxoma virus and provide a delivery method for targeted ovarian cancer therapy
por: Cornejo, Yvonne, et al.
Publicado: (2020)

Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy
por: Rahman, Masmudur M., et al.
Publicado: (2021)

Myxoma Virus-Loaded Mesenchymal Stem Cells in Experimental Oncolytic Therapy of Murine Pulmonary Melanoma
por: Jazowiecka-Rakus, Joanna, et al.
Publicado: (2020)

RNA Helicase A/DHX9 Forms Unique Cytoplasmic Antiviral Granules That Restrict Oncolytic Myxoma Virus Replication in Human Cancer Cells
por: Rahman, Masmudur M., et al.
Publicado: (2021)

Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer
por: Rahman, Masmudur M., et al.
Publicado: (2023)

Myxoma Virus-Encoded Host Range Protein M029: A Multifunctional Antagonist Targeting Multiple Host Antiviral and Innate Immune Pathways
por: Rahman, Masmudur M., et al.
Publicado: (2020)

Myxoma Virus dsRNA Binding Protein M029 Inhibits the Type I IFN-Induced Antiviral State in a Highly Species-Specific Fashion
por: Rahman, Masmudur M., et al.
Publicado: (2017)

Oncolytic Virotherapy for Hematological Malignancies
por: Bais, Swarna, et al.
Publicado: (2012)

Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor
por: Lilly, Cameron L., et al.
Publicado: (2016)

Safety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma
por: MacNeill, Amy L., et al.
Publicado: (2018)

Oncolytic Virus-Mediated RAS Targeting in Rhabdomyosarcoma
por: Phelps, Michael P., et al.
Publicado: (2018)

Autologous Transplantation Using Donor Leukocytes Loaded Ex Vivo with Oncolytic Myxoma Virus Can Eliminate Residual Multiple Myeloma
por: Villa, Nancy.Y., et al.
Publicado: (2020)

Toward comprehensive imaging of oncolytic viroimmunotherapy
por: Chaurasiya, Shyambabu, et al.
Publicado: (2021)

Convergent allostery in ribonucleotide reductase
por: Thomas, William C., et al.
Publicado: (2019)

The periodic table of ribonucleotide reductases
por: Ruskoski, Terry B., et al.
Publicado: (2021)

Oncolytic Virotherapy for Cancer: Clinical Experience
por: Chaurasiya, Shyambabu, et al.
Publicado: (2021)

Co-Regulation of NF-κB and Inflammasome-Mediated Inflammatory Responses by Myxoma Virus Pyrin Domain-Containing Protein M013
por: Rahman, Masmudur M., et al.
Publicado: (2009)

Oncolytic Herpes Simplex Virus Prevents Premalignant Lesions from Progressing to Cancer
por: Woo, Yanghee, et al.
Publicado: (2019)

Transplantation of autologous bone marrow pre-loaded ex vivo with oncolytic myxoma virus is efficacious against drug-resistant Vk*MYC mouse myeloma
por: Villa, Nancy Y., et al.
Publicado: (2022)

Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine
por: Goss, Kelli L, et al.
Publicado: (2017)

Synergistic anticancer activity of combined ATR and ribonucleotide reductase inhibition in Ewing's sarcoma cells
por: Sturm, Max-Johann, et al.
Publicado: (2023)

Vitamin D as a Primer for Oncolytic Viral Therapy in Colon Cancer Models
por: Kim, Sang-In, et al.
Publicado: (2020)

The tyrosyl free radical in ribonucleotide reductase.
por: Gräslund, A, et al.
Publicado: (1985)

Myxoma Virus Protein M029 Is a Dual Function Immunomodulator that Inhibits PKR and Also Conscripts RHA/DHX9 to Promote Expanded Host Tropism and Viral Replication
por: Rahman, Masmudur M., et al.
Publicado: (2013)

Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges
por: Chaurasiya, Shyambabu, et al.
Publicado: (2020)

Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo
por: Weng, Mingzhe, et al.
Publicado: (2014)

Combination of LIGHT (TNFSF14)-Armed Myxoma Virus Pre-Loaded into ADSCs and Gemcitabine in the Treatment of Experimental Orthotopic Murine Pancreatic Adenocarcinoma
por: Jazowiecka-Rakus, Joanna, et al.
Publicado: (2022)

An Oncolytic Poxvirus Encoding hNIS, Shows Antitumor Efficacy and Allows Tumor Imaging in a Liver Cancer Model
por: Chaurasiya, Shyambabu, et al.
Publicado: (2023)

Rational polynomial representation of ribonucleotide reductase activity
por: Radivoyevitch, Tomas, et al.
Publicado: (2005)

Ribonucleotide reductases: essential enzymes for bacterial life
por: Torrents, Eduard
Publicado: (2014)

Molecular imaging of oncolytic viral therapy
por: Haddad, Dana, et al.
Publicado: (2015)

Hydroxyurea-Mediated Cytotoxicity Without Inhibition of Ribonucleotide Reductase
por: Liew, Li Phing, et al.
Publicado: (2016)

Structural determinants and distribution of phosphate specificity in ribonucleotide reductases
por: Schell, Eugen, et al.
Publicado: (2021)

Ribonucleotide reductase, a novel drug target for gonorrhea
por: Narasimhan, Jana, et al.
Publicado: (2022)

Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present
por: Huff, Sarah E., et al.
Publicado: (2022)

Kinetic model for reversible radical transfer in ribonucleotide reductase
por: Reinhardt, Clorice R., et al.
Publicado: (2022)

A Novel Oncolytic Chimeric Orthopoxvirus Encoding Luciferase Enables Real-Time View of Colorectal Cancer Cell Infection
por: O’Leary, Michael P., et al.
Publicado: (2018)

Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma
por: Goss, Kelli L., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_v6i1bnipafu8n09t97u98jqcou